Dexlansoprazole
A modified-release proton pump inhibitor and the R-enantiomer of lansoprazole that uses a dual delayed-release formulation to provide two separate drug-release phases, maintaining acid suppression for longer periods. It is used for gastroesophageal reflux disease and erosive esophagitis.
Khối lượng phân tử
369,4000 g/mol
LogP
2,80
TPSA
87,10 Ų
Lipinski RO5
Đạt
Lĩnh vực điều trị
Cơ chế tác dụng
Irreversibly inhibits the hydrogen-potassium ATPase (proton pump) on the apical surface of gastric parietal cells. This blocks the final common pathway of gastric acid secretion, producing profound and sustained acid suppression.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Irreversibly inhibits the hydrogen-potassium ATPase (proton pump) on the apical surface of gastric parietal cells. This blocks the final common pathway of gastric acid secretion, producing profound and sustained acid …
Cấu trúc 2D
Cite this structure
Embed this structure
SMILES
Cc1c(OCC(F)(F)F)ccnc1C[S@@+]([O-])c1nc2ccccc2[nH]1
InChI
InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1
Molecular Formula
C16H14F3N3O2S
HBD / HBA
1 / 8
Liên kết có thể quay
5
Nguyên tử nặng
25
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Câu hỏi thường gặp
A modified-release proton pump inhibitor and the R-enantiomer of lansoprazole that uses a dual delayed-release formulation to provide two separate drug-release phases, maintaining acid suppression for longer periods. It is used for gastroesophageal reflux disease and erosive esophagitis.
Irreversibly inhibits the hydrogen-potassium ATPase (proton pump) on the apical surface of gastric parietal cells. This blocks the final common pathway of gastric acid secretion, producing profound and sustained acid suppression.
Yes, Dexlansoprazole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201863. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 9578005. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="dexlansoprazole"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/dexlansoprazole/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/dexlansoprazole/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/dexlansoprazole/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="dexlansoprazole"></drugfyi-drug>